On October 13, 2026, Soufflé Therapeutics, a Boston RNA therapies company, announced the close of an oversubscribed $135 million Series B financing. The round was led by Juvia Group, with new investors TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management, and a leading sovereign wealth fund joining the syndicate. Existing backers — including Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners, Breyer Capital, The Invus Group, Janus Henderson, Leaps by Bayer, Polaris Partners, Safar Partners, TAS Partners, Temasek, and Vida Ventures — also participated.
The proceeds will support the progress of Soufflé's three lead programs into clinical studies and advance its broader pipeline across additional cell types and tissues.
A Langer family venture with a heavyweight launch
Soufflé emerged from stealth in October 2025 with a $200 million Series A and partnerships with Big Pharma names including AbbVie, Amgen, Bayer, and Novo Nordisk — a debut that put more than $3.5 billion in combined fundraising and partnership value behind the company. The venture is a family affair: Moderna co-founder Robert Langer co-founded the company alongside his daughter Susan Langer, who serves as founding president and chief business officer. MIT scientists Daniel Anderson and Brad Pentelute, along with former Alnylam scientist Victor Kotelianski, round out the founding team, while CEO Amir Nashat — a veteran of Langer's MIT lab and a Polaris Partners partner — leads day-to-day operations.
That pedigree matters: Langer is one of history's most prolific drug-delivery scientists, and Soufflé's bet is that the next wave of RNA medicines will be won on delivery outside the liver.
What the REMEDY platform does
Soufflé's proprietary product engine, REMEDY (Receptor Mediated Delivery), is built to deliver oligonucleotide therapies to specific cells and tissues outside the liver. The platform systematically identifies internalizing receptors — proteins on a cell's surface that ferry cargo inside — and generates proprietary binders, such as monoclonal antibodies or other ligands, that latch onto those receptors and carry the RNA payload into the target cell.
In plain terms: where first-generation siRNA drugs mostly silence genes in the liver, Soufflé aims to give researchers a delivery toolkit for muscle, heart, and other tissues that RNA medicine has so far struggled to reach.
Three lead programs heading toward first-in-human studies
The Series B will push Soufflé's three lead programs into clinical studies:
- Facioscapulohumeral muscular dystrophy (FSHD) — a rare hereditary disorder causing lifelong, progressive loss of muscle strength, weakness in the face, shoulders, and upper body, and disability, stemming from aberrant DUX4 gene expression in muscle cells.
- Heart failure with reduced ejection fraction (HFrEF) — targeting cardiomyocytes, whose dysfunction drives a major cause of hospitalization and death worldwide.
- Muscle and metabolic disorders — an area where RNA silencing has long been conceptually attractive but delivery-limited.
The company also plans to expand the REMEDY platform to additional cell types and tissues in preclinical development.
A clinical and regulatory landscape coming into focus
Soufflé's lead program enters a disease area that is suddenly one of the most closely watched in RNA medicine. There are currently no approved therapies for FSHD, which affects an estimated 45,000 to 87,000 people in the United States and Europe. But the competitive and validation landscape has shifted fast: In February 2026 Novartis acquired Avidity Biosciences for roughly $12 billion, centered on delpacibart braxlosiran (del-brax), an antibody-oligonucleotide conjugate targeting DUX4 mRNA in FSHD now in Phase III with FDA Fast Track and Orphan Drug designations. Novartis has called it the only investigational agent showing disease-modifying potential for FSHD.
That precedent is doubly relevant for Soufflé. It validates that receptor-mediated, antibody-linked delivery of siRNA to muscle is clinically feasible — Avidity's TfR1-targeted approach improved mobility and muscle strength in Phase I/II — while also showing Big Pharma's willingness to pay at scale for extra-hepatic delivery platforms. For a young company whose entire value proposition is a cell-specific delivery engine, a $12 billion acquisition of a neighboring technology is the best possible market signal.
Dozens of companies are chasing extra-hepatic delivery across modalities — antibody conjugates, liver-evading lipid nanoparticles, and receptor-targeted systems — so Soufflé's differentiation will ultimately rest on the breadth of its receptor atlas, the durability of its binders, and clinical data. But with two large financings in twelve months, a roster of crossover and sovereign investors, and Pharma partnerships already in place, the company enters its first-in-human studies with resources that most clinical-stage RNA biotechs would envy.
What the raise means for founders and investors
Soufflé's trajectory is a case study in modern RNA biotech: launch with a transformative delivery thesis, anchor it with credible science from proven company-builders, secure Pharma validation early, then let crossover and institutional capital fund the pivot from platform to pipeline. The oversubscribed $135 million Series B — with Fidelity, Temasek, a sovereign wealth fund, and BB Biotech — signals that sophisticated capital now treats extra-hepatic RNA delivery as one of biotech's central investment themes.
For founders, the lesson is that platform breadth commands a premium: Soufflé raised $200 million before disclosing a program, on a delivery engine that could theoretically underpin many. For investors, the risk is the mirror image — platform companies live and die by the clinic, and Soufflé's three lead programs must now prove that receptor-mediated delivery translates into safe, durable, disease-modifying human medicines. The next twelve months, as first clinical data approaches, will show whether the recipe holds.
Angeled.com connects founders with investors.
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



